67th ASH Annual Meeting & Exposition

Conference Coverage

FDA Alerts

FDA ALERT

FDA ALERT

FDA Approves Pirtobrutinib For Treating Adults With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

01/26/2024

Anthony Calabro, MA

The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.

01/26/2024

Research Summaries

Conference Coverage

A Phase 2 Quadruplet Regimen Shows High MRD-Negativity Rates in Early Relapsed/Refractory Multiple Myeloma: ReKInDLE Study

12/09/2025

Kate Young

A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...

12/09/2025

Conference Coverage

Conference Coverage

Carfilzomib-Based KRd Regimen Demonstrates Superior Efficacy to VRd in Newly Diagnosed Patients with Multiple Myeloma

12/08/2025

Anthony Calabro, MA

A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...

12/08/2025

Conference Coverage

GLP-1 Receptor Agonist Use Linked to Lower Risk of MGUS Progression in Large US Cohort

12/06/2025

Ashton L. Stahl

A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...

12/06/2025

Conference Coverage

Conference Coverage

Rapid CAR-T Expansion Signals Higher Delayed Neurotoxicity Risk After Cilta-cel

12/06/2025

Ashton L. Stahl

In a multicenter US study of patients with relapsed/refractory multiple myeloma receiving commercial ciltacabtagene autoleucel, investigators examined whether rapid peak CAR T-cell expansion and absolute...

12/06/2025

Conference Coverage

Mosunetuzumab as a Treatment Option for Patients With Relapsed or Refractory Mantle Cell Lymphoma

12/10/2024

Anthony Calabro, MA

Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...

12/10/2024

April 2026

Current Issue

April 2026